[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644499":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":26,"locations":32,"responsibleParty":46,"collaborators":11,"id":48,"slug":11,"hasResults":49,"nctId":50,"briefTitle":9,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":49,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"RayzeBio, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Imaging Study of a CAIX Binder in Metastatic Clear Cell RCC.","EXPERIMENTAL",null,[13],"Diagnostic Test: RYZ512",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","RYZ512","Imaging Agent",[9],[21,24],{"name":22,"affiliation":5,"role":23},"Freddy Escorcia, MD, PhD","STUDY_DIRECTOR",{"name":25,"affiliation":5,"role":23},"Heying Duan, MD",[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"RayzeBio Clinical Trials","CONTACT","(619) 657-0057","clinicaltrials@rayzebio.com",[33],{"facility":34,"status":11,"city":35,"state":11,"zip":11,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Research Facility","Christchurch","New Zealand",{"type":38,"coordinates":39},"Point",[40,41],172.63333,-43.53333,{"lat":41,"lon":40},[44],{"name":45,"role":29,"phone":11,"phoneExt":11,"email":11},"Site Contact",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100644499",false,"NCT07671417","A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of a Carbonic Anhydrase IX (CAIX) Binder in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).","Inclusion Criteria:\n\n* At least 18 years old at the time of signing the informed consent form (ICF).\n* Biopsy proven metastatic clear cell renal cell carcinoma (RCC)\n\nExclusion Criteria:\n\n* Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides\n* Women of Childbearing Potential that are pregnant or breastfeeding.\n\nNote: Additional criteria may apply and will be assessed by the study site","ALL","18 Years",{"count":56,"type":57},10,"ESTIMATED","INTERVENTIONAL",[60],"EARLY_PHASE1","This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a novel Carbonic Anhydrase IX (CAIX) Binder in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).",[63],"Metastatic Clear Cell Renal Cell Carcinoma",[65,66,67,68,69,70,71,72,73,74,18],"RCC","Metastatic RCC","Metastatic Clear Cell Renal Cancer","CAIX","CA9","RayzeBio","Rayze","BMS","Bristol Myers Squibb","RPT","NOT_YET_RECRUITING","2026-06-22",{"date":78,"type":79},"2026-06-26","ACTUAL",{"date":81,"type":57},"2026-06",{"date":83,"type":57},"2027-01",{"name":5,"class":6},1]